Technology Bundle ID
TAB-2694

Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

Linked ID
E-210-2013-0
Lead Inventors
Anne Boyer (CDC)
Jason Goldstein (CDC)
Co-Inventors
Conrad Quinn (CDC)
Dennis Bagarozzi (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
  • Early-stage
  • In vitro data available
ICs
CDC
CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax vaccine.
Commercial Applications
  • Diagnostic tests assessing active Lethal Factor in a sample
  • Anthrax neutralizing therapeutics and vaccines for B. anthracis
  • Biodefense, biosecurity
Competitive Advantages
  • Potentially faster, lower-input assay compared to current Edema Factor detection methods
  • Easily adaptable for high-throughput screening of numerous specimens

Request More Info

Licensing Contact: